The 46 references in paper S. Rachina A., R. Kozlov S., Yu. Belkova A., С. Рачина А., Р. Козлов С., Ю. Белькова А. (2015) “Фармакоэпидемиология: от теоретических основ к практическому применению // PHARMACOEPIDEMIOLOGY: FROM THEORY TO PRACTICE” / spz:neicon:pharmacoeconomics:y:2014:i:1:p:33-39

1
Bel'kova Ju.A., Rachina S.A., Kozlov R.S., Mishhenko V.M., Kozhuhova L.L. , Abubakirova A.I. i soavt. Potreblenie i zatraty na sistemnye antimikrobnye preparaty v mnogoprofil'nyh stacionarah Rossijskoj Federacii i Respubliki Belarus': rezul'taty mnogocentrovogo farmakojepidemiologicheskogo issledovanija. Klin. mikrobiol. antimikrob. himioter. 2012; 14: 322-41.
(check this in PDF content)
2
Bodjaeva E.V. Rachina S.A., Otvagin I.V., Gudkov I.V. Analiz jeffektivnosti kompleksnogo vmeshatel'stva u pacientov s ostrym tonzillofaringitom v ambulatornoj praktike Smolenska. Klin. mikrobiol. antimikrob. himioter. 2011; 13: 46-55.
(check this in PDF content)
3
Golub A.V. Pokazateli kachestva i puti uluchshenija antibakterial'noj profilaktiki v abdominal'noj hirurgii. Avtoref diss. ... kand. med. nauk. Smolensk. 2007; 23 s.
(check this in PDF content)
4
Kliniko-jekonomicheskie issledovanija. Dostupno na sajte: http:// www.hta-rus.ru/research-2/.
(check this in PDF content)
5
Kozlov S.N. Farmakojepidemiologicheskie podhody k optimizacii lekarstvennoj terapii vnebol'nichnyh infekcij v ambulatornyh uslovijah. Avtoref. diss. ...dokt. med. nauk. Smolensk. 2004. 37 s.
(check this in PDF content)
6
Kozlov S.N., Rachina S.A., Andreeva I.V. Farmakojepidemiologija antiinfekcionnyh himiopreparatov. V kn.: L.S. Strachunskogo, Ju.B. Belousova, S.N. Kozlova. Praktiicheskoe rukovodstvo po antiinfekcionnoj himioterapii. Smolensk. 2007; 47-55.
(check this in PDF content)
7
Kozlov S.N., Rachina S.A., Strachunskij L.S. Farmakojepidemiologija. V kn.: V.G. Kukesa, A.K. Starodubceva. Klinicheskaja farmakologija i farmakoterapija. M. 2003; 134-136.
(check this in PDF content)
8
Leonova M.V., Belousov D.Ju., Shtejnberg L.L., Galickij A.A., Belousov Ju.B., analiticheskaja gruppa issledovanija PIFAGOR. Pervye rezul'taty farmakojepidemiologicheskogo issledovanija arterial'noj gipertonii PIFAGOR III. Kachestvennaja klinicheskaja praktika 2010; 1: 54-60.
(check this in PDF content)
9
Prikladnaja farmakojepidemiologija. Uchebnik pod red. akademika RAMN V.I. Petrova. M. 2008; 384 s.
(check this in PDF content)
10
Rachina S.A. Optimizacija ispol'zovanija antimikrobnyh preparatov v mnogoprofil'nom stacionare: chem mozhet byt' polezen analiz real'noj klinicheskoj praktiki? Moskovskij medicinskij zhurnal. 2012; 3: 5-11.
(check this in PDF content)
11
Rachina S.A., Andreeva A.S., Bedenkov A.V. ATC/DDD metodologija: osnovnye principy i prakticheskoe ispol'zovanie v issledovanijah potreblenija lekarstvennyh sredstv. Klinicheskaja farmakoloigja i terapija 2002; 11: 44-8.
(check this in PDF content)
12
Fletcher R., Fletcher S., Vagner E. Klinicheskaja jepidemiologija. Osnovy dokazatel'noj mediciny. 3-e izd. Perevod s angl. pod red. S.E. Bashhinskogo, S.Ju. Varshavskogo. M. 1998; 382 c.
(check this in PDF content)
13
Fokin A.A., Rachina S.A., Kozlov S.N. Issledovanija ispol'zovanija lekarstvennyh sredstv: metodologija provedenija i perspektivy prakticheskogo primenenija v Rossii. Klinicheskaja farmakologija i terapija. 2009; 18 (1): 1-7.
(check this in PDF content)
14
Shal' E.P. Kliniko-jekonomicheskie i farmakojepidemiologicheskie aspekty antibakterial'noj terapii respiratornyh infekcij v ambulatornoj praktike. Avtoref. diss. kand. med. nauk. Smolensk. 2013; 27 s.
(check this in PDF content)
15
Bombardier C. Research challenges; overview of epidemiological study design. J. Reumatol. 1998; 15 (17): 5-8.
(check this in PDF content)
16
Drug utilization studies. Methods and uses. Edited by Dukes M.N.G. WHO Regional Publications, European Series, WHO Regional Office for Europe. Copenhagen. Denmark. 1993; 45.
(check this in PDF content)
17
Educational Programs in Pharmacoepidemiology. Available from: http:// www.pharmacoepi.org/resources/programs.cfm.
(check this in PDF content)
18
Einarson T.R., Bergman U., Wiholm B.-E. Principles and practice of pharmacoepidemiology. In: Speight T.M., Holford N.H.G., editors. Avery’s Drug Treatment. 4th ed. New Zealand: Adis International Limited. 1997; 371-392.
(check this in PDF content)
19
Engel A., Siderius P. The consumption of drugs. Report on a study 1966-1967. Copenhagen. WHO Regional Office for Europe. 1968 (EURO 3101).
(check this in PDF content)
20
European Drug Utilization Research Group. Available from: http:// www.eurodurg.com/.
(check this in PDF content)
21
Guidelines for Good Pharmacoepidemiology Practices. Available from: http:// www.pharmacoepi.org/resources/guidelines_08027.cfm.
(check this in PDF content)
22
Guidelines for ATS classification and DDD assignment. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology. 2005.
(check this in PDF content)
23
Haaijer-Ruskamp F.M., Andersen M., Vander Stichele R.H. Prescribing Quality Indicators. In: Hartzema A.G., Tilson H.H, Chan K.A, editors. Pharmacoepidemiology and therapeutic risk assessment. Harwey Whitney Books, Cincinatti. 2008; 197-218.
(check this in PDF content)
24
Hartzema A.G. Pharmacoepidemiology – its relevance to clinical practice. J. Clin. Pharm. and Therapeutics. 1992; 17: 73-74.
(check this in PDF content)
25
Hartzema A.G., Tilson H.H., Chan K.A. The Contribution of Pharmacoepidemiology to the Study of Drug Uses and Effects, and Risk Management. In: Hartzema A.G., Tilson H.H, Chan K.A, editors. Pharmacoepidemiology and therapeutic risk assessment. Harwey Whitney Books, Cincinatti. 2008; 1-38.
(check this in PDF content)
26
Jones J.K., Tilson H.H., Lewis J.D. Pharmacoepidemiology: defining the field and its core content. Pharmacoepidemiol Drug. Saf. 2012; 21 (7): 677-689.
(check this in PDF content)
27
Kennedy D. Assessing national drug utilization in the United States. WHO Drug Utilization Research Group Meeting. 1983 Aug 5; Washington, USA.
(check this in PDF content)
28
Kurth T., Seeger J.D. Propensity Score Analyses in Pharmacoepidemiology. In: Hartzema A.G., Tilson H.H, Chan K.A, editors. Pharmacoepidemiology and therapeutic risk assessment. Harwey Whitney Books, Cincinatti. 2008. p. 301-24.
(check this in PDF content)
29
Lee J.A.H., Draper P.A., Weatherall M. Prescribing in three English towns. Milbank Mem Fund Q 1965; 43: 285-290.
(check this in PDF content)
30
McBride W.G. Thalidomide and congenital abnormalities. Lancet. 1961; 2: 1358.
(check this in PDF content)
31
Meade T.W. Prescribing of chloramphenicol in general practice. BMJ. 1967; 1: 671-674.
(check this in PDF content)
32
Ronning M. Setting-up the WHO ATC classification of drugs and the Defined Daily Dose – problems and potential for standardizing drug use research worldwide. In: McGavock H., editor. Handbook of Drug Use Research Methodology. 1st ed. Newcastle: The United Kingdom Drug Utilization Research Group; 2000; 1-9.
(check this in PDF content)
33
Serradel J.S., Bjornson D.C., Hartzema A.G. Drug utilization study methodologies: national and international perspectives. Drug. Intell. Clin. Pharm. 1987; 21: 994-1001.
(check this in PDF content)
34
Stratchounski L.S., Andreeva I.V., Ratchina S.A., Galkin D.V., Petrotchenkova N.A., Demin A.A. et al. The inventory of antibiotics in Russian home medicine cabinets. Clin. Infect. Dis. 2003; 15; 37 (4): 498-505.
(check this in PDF content)
35
Strom B.L. Study Designs Available for Pharmacoepidemiology Studies. In: Strom B.L., editor. Pharmacoepidemiology. 3d ed. New York: John Wiley & Sons, Inc. 2000; 17-30.
(check this in PDF content)
36
Strom B.L. What is pharmacoepidemiology? In: Strom B.L., editor. Pharmacoepidemiology. 3d ed. New York: John Wiley & Sons, Inc.; 2000; 3-16.
(check this in PDF content)
37
Strom B.L. When Should One Perform Pharmacoepidemiology Studies? In: Strom B.L., editor. Pharmacoepidemiology. 3d ed. New York: John Wiley & Sons, Inc. 2000; 63-72.
(check this in PDF content)
38
Suruki R.Y., Chan K.A. Basic Pharmacoepidemiology Methods. In: Hartzema A.G., Tilson H.H, Chan K.A, editors. Pharmacoepidemiology and therapeutic risk assessment. Harwey Whitney Books, Cincinatti. 2008; 219-38.
(check this in PDF content)
39
The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on Methodological Standards in Pharmacoepidemiology (Revision 2). EMA/95098/2010. Available at http://www.encepp.eu/standards_and_guidances.
(check this in PDF content)
40
Urquhart J. Role of pharmacoepidemiology in drug development. Int. J. Clin. Pharm. Ther and Toxicol. 1992; 30: 456-458.
(check this in PDF content)
41
Verhamme K., Sturkenboom M. Study designs in paediatric pharmacoepidemiology. Eur. J. Clin. Pharmacol. 2011; 67 (1): 67-74.
(check this in PDF content)
42
Wettermark B. The intriguing future of pharmacoepidemiology. Eur. J. Clin. Pharmacol. 2013; 69 (1): 43-51.
(check this in PDF content)
43
Wettermark B., Vlahovic-Palcevski V., Salvesen Blix H., Rønning M., Vander Stichele R.H. Drug utilization research. In: Hartzema A.G., Tilson H.H, Chan K.A, editors. Pharmacoepidemiology and therapeutic risk assessment. Harwey Whitney Books, Cincinatti; 2008. p. 159-95.
(check this in PDF content)
44
WHO Drug Utilization Research Group (DURG). Validation of observed differences in the utilization of antihypertensive and antidiabetic drugs in Northern Ireland, Norway and Sweden. Eur. J. Clin. Pharmacol. 1985; 29: 1-8.
(check this in PDF content)
45
Wilson-Davis K. Study design and the use of statistics in drug use research. In: McGavock H., editor. Handbook of Drug Use Research Methodology. 1st ed. Newcastle: The United Kingdom Drug Utilization Research Group. 2000; 36-55.
(check this in PDF content)
46
World Health Organization Expert Committee. The selection of essential drugs. Geneva: World Health Organization, 1977. PHARMACOEPIDEMIOLOGY: FROM THEORY TO PRACTICE Rachina S.A., Kozlov R.S., Belkova Yu.A. Smolensk State Medical Academy
(check this in PDF content)